Comparative Pharmacology
Head-to-head clinical analysis: ESTAZOLAM versus NIRAVAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTAZOLAM versus NIRAVAM.
ESTAZOLAM vs NIRAVAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzodiazepine that binds to GABA-A receptors at the alpha-1 subunit, enhancing the effect of GABA by increasing chloride ion conductance, leading to neuronal hyperpolarization and CNS depression.
NIRAVAM (alprazolam) is a benzodiazepine that potentiates GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and decreased excitability.
1-2 mg orally at bedtime.
0.25–0.5 mg sublingually every 6–8 hours as needed; maximum 2 mg/day.
None Documented
None Documented
Terminal elimination half-life: 10-24 hours (mean ~17 hours); prolonged in elderly and hepatic impairment.
Clinical Note
moderateEstazolam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Estazolam is combined with Fluticasone propionate."
Clinical Note
moderateEstazolam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Estazolam."
Clinical Note
moderateEstazolam + Erythromycin
"The serum concentration of Erythromycin can be increased when it is combined with Estazolam."
Clinical Note
moderateEstazolam + Cyclosporine
Terminal elimination half-life: 8–14 hours (mean 10.5 h). Clinically, steady-state reached in ~3 days; accumulation minimal at typical dosing.
Renal: ~90% as metabolites, <1% unchanged. Fecal: small amount, ~10%.
Renal: ~90% as metabolites (glucuronide conjugates and oxidized products), <5% unchanged. Fecal: <10%.
Category D/X
Category C
Benzodiazepine
Benzodiazepine
"The metabolism of Cyclosporine can be decreased when combined with Estazolam."